期刊文献+

基于分子对接研究吲哚咔唑类小分子对Tie-2/VEGFR2的双效抑制作用模式 被引量:1

Studies on Interactions between Tie-2/VEGFR2 and Dihydroindazolocarbazole Dual Inhibitors via Molecular Docking
在线阅读 下载PDF
导出
摘要 运用分子对接技术研究了吲哚咔唑类小分子对人血管内皮生长因子受体2(VEGFR2)和人血管生成素受体Tie-2(ANG-R-Tie-2)的双效抑制作用模式。研究结果表明,吲哚咔唑类小分子的双效抑制作用主要源于两种受体相似的活性口袋,小分子与两者的铰链区均可形成氢键,使其催化活性受到抑制,从而抑制肿瘤细胞的生长。抑制活性的差异主要源于活性口袋的细微差异所导致疏水、静电等相互作用的不同。其中,疏水作用的差异是影响配体选择性的主要原因,静电作用、氢键及空间位阻对结合稳定也有一定影响。该文的研究结果为多靶点酪氨酸激酶小分子抑制剂的设计及提高激酶抑制剂的选择性提供了重要的理论依据。 Dihydroindazolocarbazoles (DHI-carbazoles) are the potent dual inhibitors to VEGFR2 and Tie-2. In this work, the mechanism of interaction between VEGFR2/Tie-2 and DHI-carbazoles was per- formed with Surflex-dock. The results from molecular docking indicated that DHI-carbazoles competitivelybound to the active site, which was the substrate ATP in VEGFR2/Tie-2 with high affinity. The differ- ences of activity between VEGFR2 and Tie-2 resulted from the minor difference of active pockets. Hydro- phobic effect played a key role in the formation and stability. Hydrogen bond and electrostatic effect also contributed to the difference. This work elucidated the antitumor mechanism of the DHI-carbazoles as a dual potent inhibitor and provided theoretical basis for the design of tyrosine kinase inhibitors.
出处 《中山大学学报(自然科学版)》 CAS CSCD 北大核心 2012年第2期66-72,共7页 Acta Scientiarum Naturalium Universitatis Sunyatseni
基金 国家自然科学基金资助项目(81001423) 南方医科大学课外学术活动资助项目
关键词 吲哚咔唑类抑制剂 VEGFR2 TIE-2 分子对接 molecular docking tyrosine kinase inhibitors VEGFR2 Tie-2
  • 相关文献

参考文献18

  • 1CRIVELLATO E.The role of angiogenic growth factors inorganogenesis[J].International Journal of DevelopmentalBiology,2011,55(4-5):365-375.
  • 2SAHARINEN P,BRY M,ALITALO K.How do angio-poietins Tie in with vascular endothelial growth factors?[J].Current Opinion in Hematology,2010,17(3):198-205.
  • 3MAKINDE T,AGRAWAL D K.Intra and extravasculartransmembrane signalling of angiopoietin-1-Tie2 receptorin health and disease[J].Journal of Cellular and Molec-ular Medicine,2008,12(3):810-828.
  • 4WERMUTH C G.The Practice of Medicinal Chemistry[M].New York:Academic Press,2008:549-571.
  • 5刘靖,王林,杨晓明.多靶点蛋白酪氨酸激酶抑制剂的研究进展[J].国际药学研究杂志,2009,36(3):161-171. 被引量:22
  • 6HUDKINS R L,ZULLI A L,UNDERINER T L,et al.8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors[J].Bioorganic&Medicinal Chemistry Letters,2010,20(11):3356-3360.
  • 7TIAN Y,XU J,LI Z,et al.Combined 3D-QSAR anddocking modelling study on indolocarbazole series com-pounds as tie-2 inhibitors[J].International Journal ofMolecular Sciences,2011,12(8):5080-5097.
  • 8DANDU R,ZULLI A L,BACON E R,et al.Design andsynthesis of dihydroindazolo[5,4-a] pyrrolo[3,4-c] car-bazole oximes as potent dual inhibitors of TIE-2 andVEGF-R2 receptor tyrosine kinases[J].Bioorganic&Medicinal Chemistry Letters,2008,18(6):1916-1921.
  • 9BECKNELL N C,ZULLI A L,ANGELES T S,et al.Novel C-3 N-urea,amide,and carbamate dihydroindazolo[5,4-a] pyrrolo[3,4-c] carbazole analogs as potent TIE-2and VEGF-R2 dual inhibitors[J].Bioorganic&Medici-nal Chemistry Letters,2006,16(20):5368-5372.
  • 10UNDERINER T L,RUGGERI B,AIMONE L,et al.TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyldihydroindazolo[5,4-a] pyrrolo[3,4-c] carbazole ana-logs[J].Bioorganic&Medicinal Chemistry Letters,2008,18(7):2368-2372.

二级参考文献134

  • 1郭权,王希诚,李纯莲.药物分子对接中应用网格的研究与进展[J].计算机研究与发展,2004,41(12):2054-2059. 被引量:7
  • 2Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 3De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 4Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 5Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 6Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 7Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 8Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
  • 9Hanrahan EO,Heymach JV.Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer[J].Clin Cancer Res,2007,13(15):4617-4622.
  • 10Arnold AM,Seymour L,Smylie M,et al.Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy:National Cancer Institute of Canada Clinical Trials Group Study BR.20[J].J Clin Oncol,2007,25(27):4278-4284.

共引文献122

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部